Last reviewed · How we verify
Investigational Tdap vaccine Formulation C
Investigational Tdap vaccine Formulation C is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational Tdap vaccine Formulation C |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational Tdap vaccine Formulation C CI brief — competitive landscape report
- Investigational Tdap vaccine Formulation C updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Investigational Tdap vaccine Formulation C
What is Investigational Tdap vaccine Formulation C?
Investigational Tdap vaccine Formulation C is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Investigational Tdap vaccine Formulation C?
Investigational Tdap vaccine Formulation C is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Investigational Tdap vaccine Formulation C in?
Investigational Tdap vaccine Formulation C is in Phase 1.